Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBenjamin T Diamond, MD
About this trial
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.
Eligibility criteria
Qualifiers
Serum monoclonal protein ≥ 1.0 g/dL
Urine monoclonal protein ≥ 200 mg/24 hour
Involved serum immunoglobulin free light chains (FLC) ≥ 10 mg/dL AND abnormal kappa/lambda ratio.
Best response achieved during CD38-directed therapy was ≥ PR.
Disqualifiers
Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted.
Patients may receive kyphoplasty/vertebroplasty for symptomatic vertebral compression fractures.
Bone targeting agents are permitted.
Concurrent or prior treatment with corticosteroids for indications other than MM is permitted.
Trial design
Treatments tested in this trial
- Iberdomide
- Carfilzomib
- Daratumumab
- Dexamethasone
- Acetaminophen
- Diphenhydramine
- Montelukast
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Benjamin T Diamond, MD
Lead sponsor
University of Miami
Sponsor institution
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov